FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
February 27 2023 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner,
M.D., M.P.H., Chief Medical Officer, will participate in a panel
discussion at Cowen’s 43rd Annual Health Care Conference to be held
in Boston on March 5 - 8, 2023. Details of the presentations are as
follows:
Panel Information:Date: Wednesday, March 8,
2023Panel topic: Respiratory/Infections Time: 10:30 AM Eastern
Time
A live audio webcast of the event will be available to investors
and other interested parties on the “Events & Presentations”
section of the FibroGen Investor webpage at www.fibrogen.com. A
replay will be available for approximately 30 days.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in connective tissue
growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to
advance innovative medicines for the treatment of unmet needs.
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical
development for the treatment of idiopathic pulmonary fibrosis
(IPF), locally advanced unresectable pancreatic cancer (LAPC),
metastatic pancreatic cancer, and Duchenne muscular dystrophy
(DMD). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China,
Europe, Japan, and numerous other countries for the treatment of
anemia in CKD patients on dialysis and not on dialysis. Roxadustat
is in Phase 3 clinical development in the U.S. and Europe for
anemia associated with myelodysplastic syndromes (MDS), and in
Phase 3 clinical development in China for treatment of
chemotherapy-induced anemia (CIA). FibroGen recently expanded its
research and development portfolio to include product candidates in
the immuno-oncology and autoimmune space. For more information,
please visit www.fibrogen.com.
Contacts:FibroGen,
Inc.Investors:Michael Tung, M.D.Corporate
Strategy / Investor Relations415.978.1434mtung@fibrogen.com
Media:Meichiel KeenanInvestor Relations and
Corporate Communicationsmkeenan@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024